Intertek has acquired a a new 20,000 sq. ft facility in Melbourn, UK, doubling the size of its existing laboratory facilities at that location, the company said. As part of the expansion, Intertek said, the company plans to hire approximately 100 new employees over 4 years.
The new facility, which should open by the end of the year, will have additional space for inhalation and nasal drug testing, including laboratory space specifically for inhaled biologics formulation development. Intertek acquired the existing Melbourn facility in 2013 when it acquired OINDP testing specialist Melbourn Scientific.
Intertek UK & Eire Chief Executive Rob van Dorp commented, “We are delighted to expand and invest in inhalation and nasal product testing for biologics and pharmaceuticals at our Melbourn site, as global demand grows for specialists contract laboratory services. This latest expansion brings increased capacity and flexibility and will help to deliver a superior customer service for our clients around the world. Integrated with the teams’ outstanding expertise in analytical and formulation support for the pharmaceutical, biotechnology and drug delivery industries, we can effectively help our clients to meet milestones for their challenging pharmaceutical development programs through our systemic, end-to-end Total Quality Assurance solutions.”
Read the Intertek press release.
